Table 1 Baseline characteristics.

From: Anti-VEGF treatment outcome prediction based on optical coherence tomography images in neovascular age-related macular degeneration using a deep neural network

Variables

Neovascular AMD (N = 517)

Age, years (IQR)

71.4 (65–78, median 72)

Sex, n (%)

 Male

311 (60)

 Female

206 (40)

Eye treated, n (%)

 Right

272 (53)

 Left

245 (47)

Underlying disease, n (%)

 Hypertension

245 (46)

 Diabetes

107 (21)

Subtypes of wet AMD, n (%)

 PCV

167 (32)

 Type 1 MNV, except PCV

110 (22)

 Type 2 MNV

178 (34)

 RAP (type 3 MNV)

62 (12)

Treatment response, n (%)*

 Dry macula

409 (79)

 SRF remained

85 (16)

 IRF remained

23 (5)

Visual acuity (logMAR, IQR)†

 Pre-injection

0.43 (0.15–0.52, median 0.30)

 1-month after first injection

0.36 (0.10–0.52, median 0.30)

 1-month after second injection

0.31 (0.10–0.40, median 0.22)

 1-month after third injection

0.29 (0.10–0.40, median 0.22)

  1. AMD age-related macular degeneration, IQR interquartile range, PCV polypoidal choroidal vasculopathy, MNV macular neovascularization, RAP retinal angiomatous proliferation, SRF subretinal fluid, IRF intraretinal fluid, logMAR logarithm of the minimum angle of resolution.
  2. *After administering injections three monthly injections, the evaluation was conducted one month after the last injection using OCT (optical coherence tomography).
  3. †Only the 203 individuals for whom visual acuity data could be obtained were listed.
Back to article page